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Available online 4 January 2018An induced pluripotent stem cell (iPSC) linewas generated from a 36-year-old patientwith sporadic Parkinson's
disease (PD). Skin ﬁbroblasts were reprogrammed using the non-integrating Sendai virus technology to deliver
OCT3/4, SOX2, c-MYC and KLF4 factors. The generated cell line (CSC-43) exhibits expression of common
pluripotency markers, in vitro differentiation into three germ layers and normal karyotype. This iPSC line can
be used to study the mechanisms underlying the development of PD..
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Dopaminergic neurons obtained from the differentiation of sporadic
Parkinson's disease (PD) patient derived - induced pluripotent stem
cells (iPSCs) have been shown to express a pathogenic phenotype, in-
cluding morphological alterations and accumulation of autophagic vac-
uoles (Sánchez-Danés et al., 2012). Here we report the generation of an
induced pluripotent stem cell line (CSC-43) from a patient with early-
onset PD with no identiﬁed genetic cause, which can be used to under-
stand the molecular basis of this neurodegenerative disease.Fig. 1. Characterization ofTo generate CSC-43 iPSC line, skinﬁbroblasts collected bypunch skin
biopsy from a 36-year-old PD patient were reprogrammed using a non-
integrating Sendai virus technology. Brieﬂy, ﬁbroblasts were seeded
(75,000 cells/well) on a 12-well plate, two days before transduction.
The CytoTune™-iPS 2.0 Sendai ReprogrammingKitwas then used to de-
liver the four reprogramming factors, OCT3/4, SOX2, c-MYCandKLF4. At
day 7 post-transduction, the cells were re-seeded onto mouse embry-
onic ﬁbroblasts (MEF)-feeder layer and expanded until colonies pre-
sented an embryonic stem cell (ES)-like morphology. At day 28, 12
colonies were picked and expanded as individual clones for 7 days.the iPSC line CSC 43J.
84 A. Marote et al. / Stem Cell Research 27 (2018) 82–85Three clones (CSC-43D, CSC-43I and CSC-43J) were further selected for
expansion and karyotype analysis. All clones were characterized using
the methods we previously described (Holmqvist et al., 2016). We re-
port, herein the characterization of clone CSC-43J.
The generated clone, CSC-43J, expressed the common nuclear and
cell surface pluripotency markers, OCT4/Nanog and TRA1-81/SSEA4
(Fig. 1A) and showed alkaline phosphatase (ALP) activity (Fig.1B).
Flow cytometry analysis showed N99% of the iPSCs positive for SSEA4
(Fig. 1C; non-stained iPSCs are shown in grey). Additional immunocyto-
chemistry analysis revealed elimination of the Sendai virus at passage 8
(Fig. 1D). Fig. 1E depicts a normal male karyogram identiﬁed in CSC-43J
clone. Embryoid bodies (EBs) generated from CSC-43J iPSC present
three-germ layer differentiation capacity as shown by the in vitro ex-
pression of alpha-fetoprotein (AFP), an endodermal marker, smooth
muscle actin (SMA), a mesodermal marker, and beta-III tubulin
(BIIITub), an ectodermal marker (Fig. 1F). The identity of the generated
iPSC line was conﬁrmed by DNA ﬁngerprint, showing genetic corre-
spondence to parentalﬁbroblasts. Mycoplasma infectionwas prevented
by routine addition of plasmocin in cell culturemedia, at early passages.
Materials and methods
Fibroblast culture
Dermal ﬁbroblasts were collected by punch skin biopsy from a pa-
tient diagnosed with PD, after obtaining informed consent. The ﬁbro-
blasts were maintained in ﬁbroblast growth medium, composed of
DMEM media (ThermoFisher Scientiﬁc) with 10% fetal bovine serum
and 1% Penicillin-Streptomycin and passaged with 0.05% trypsin.
iPSC generation and expansion
For reprogramming, 75,000 cells were seeded on a 12-well plate and
maintained in ﬁbroblast growth medium. Two days after (day 0), the
cells were transduced using the three vector preparations (MOI = 5,
5, 3) included in the CytoTune™-iPS 2.0 Sendai Reprogramming Kit
(ThermoFisher Scientiﬁc). On the following day and on every other
day, the medium was replaced with fresh ﬁbroblast growth medium.
At day 7, the cells were re-seeded onto irradiated mouse embryonic ﬁ-
broblasts (MEFs) feeder cells with ﬁbroblast growth medium. On the
day after and until colony picking, the cells were cultured inWiCell me-
dium composed of advanced DMEM/F12 (ThermoFisher Scientiﬁc), 20%
Knock-Out Serum Replacement (v/v, ThermoFisher Scientiﬁc), 2 mM L-
glutamine (ThermoFisher Scientiﬁc), 1% non-essential amino acids
(NEAA, v/v, Millipore) and 0.1 mM β-mercaptoethanol, supplementedTable 1
Characterization and validation.
Classiﬁcation Test Result
Morphology Photography Visual record of the line: Normal
Phenotype Immunocytochemisty Positive staining for pluripotency
Alkaline phosphatase
activity
Visible activity
Flow cytometry 99.7% SSEA4
Genotype Karyotype (G-banding)
and resolution
46,XY (300–400 bands resolution
Identity STR analysis 10 sites analyzed, all matched wi
Mutation analysis (if
applicable)
N/A N/A
Microbiology and
virology
Mycoplasma Mycoplasma testing by RT-PCR. N
Differentiation potential Embryoid body formation Staining of smooth muscle actin,
spontaneous differentiation of em
Donor screening
(optional)
HIV 1 + 2 Hepatitis B,
Hepatitis C
N/A
Genotype additional info
(optional)
Blood group genotyping N/A
HLA tissue typing N/Awith 20 ng/ml FGF2 (ThermoFisher Scientiﬁc). On day 28, individual
colonies were picked and re-seeded on a 24-well plate containing
fresh MEFs. One week after, three clones were selected and further ex-
panded on 6-well plates. The cells were passaged once a week and
seeded on the appropriate cell culture surface for characterization as-
says at the indicated passage numbers (Table 1).
Immunocytochemistry
The iPSCs cultures were ﬁxed with 4% paraformaldehyde for 15min
at room temperature (RT), permeabilized and blocked for 1 h at RTwith
PBS containing 10% donkey serum and 0.1% TritonX-100 (Sigma) and
incubated overnight at +4 °C with the primary antibodies (Table 2) di-
luted in the blocking buffer. The secondary antibodies were thereafter
added for 1 h at RT in the dark, followed by nuclei counterstain with
DAPI (1:10,000 (Life Technologies)) and image acquisition on inverted
epiﬂuorescence microscope LRI - Olympus IX-73. Scale bars are 200μm.
Alkaline phosphatase activity
Alkaline phosphatase staining was performed using Alkaline Phos-
phatase Staining Kit (Stemgent, MA).
In vitro differentiation by embryoid body (EB) formation
Human iPSC were grown for 2 weeks as embryoid bodies (EBs) in
low-attachment 24-well plates (Corning) in WiCell medium supple-
mented with 20 ng/ml FGF2. The EBs were then seeded on a 0.1% gela-
tin-coated 96-well plate (Greiner Bio-One) in DMEMmedia containing
10% fetal bovine serum and 1% Penicillin-Streptomycin for subsequent
spontaneous differentiation, with media changes every 2–3 days. After
2 weeks, the cells were ﬁxed and stained for three germ-layer markers
as described in Table 2.
Karyotype analysis
The G-banding analysis was performed at 300–400 band resolution
in average after 11 passages, at the Department of Clinical Genetics
and Pathology in Lund.
DNA ﬁngerprinting
Genomic DNA from ﬁbroblasts and hiPSCs was extracted using con-
ventional lysis buffer composed of 100mMTris (pH 8.0), 200mMNaCl,
5 mM EDTA and 0.2% SDS in distilled autoclaved water supplementedData
Not shown but available
with the author
markers: OCT4, NANOG, TRA1-81 and SSEA4 Fig. 1 panel A
Fig. 1 panel B
Fig. 1 panel C
in average) Fig. 1 panel E
th parent ﬁbroblast cell line Available with the author
N/A
egative. Not shown but available
with author
beta-III-tubulin and alpha-fetoprotein after
bryoid bodies
Fig. 1 panel F
N/A
N/A
N/A
Table 2
Reagents details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency markers Mouse anti-Oct4 1:200 Millipore Cat# MAB4401, RRID:AB_2167852
PE-conjugated mouse anti-human Nanog 1:200 BD Biosciences Cat# 560483, RRID:AB_1645522
Mouse anti- TRA-1-81 1:200 Thermo Fisher Scientiﬁc Cat# 41-1100, RRID:AB_2533495
PE-conjugated mouse anti-SSEA4 1:200 Thermo Fisher Scientiﬁc Cat# A14766, RRID:AB_2534281
Sendai Chicken anti-Sendai virus 1:1000 Abcam Cat# ab33988, RRID:AB_777877
Differentiation Markers Mouse anti-AFP 1:200 Sigma-Aldrich Cat# A8452, RRID:AB_258392
Mouse anti-SMA 1:200 Sigma-Aldrich Cat# A2547, RRID:AB_476701
Mouse anti-BIII tubulin 1:200 Sigma-Aldrich Cat# T8660, RRID:AB_477590
Secondary antibodies Donkey anti-mouse Alexa Fluor® 488 1:400 Molecular Probes Cat# A-21202, RRID:AB_141607
Donkey anti-chicken Alexa Fluor® 488 1:400 Jackson ImmunoResearch Labs Cat# 703-545-155, RRID:AB_2340375
Donkey anti-mouse Alexa Fluor® 555 1:400 Thermo Fisher Scientiﬁc Cat# A-31570, RRID:AB_2536180
85A. Marote et al. / Stem Cell Research 27 (2018) 82–85with 1.5 mg/ml Proteinase K. Fingerprinting analyses were outsourced
to the IdentiCell STR proﬁling service (Department of Molecular Medi-
cine, Aarhus University Hospital, Skejby, Denmark).
Mycoplasma detection
Absence of mycoplasma contamination was conﬁrmed by the real-
time PCRmethod at GATC Biotech AG (European Genome and Diagnos-
tics Centre, Konstanz, Germany).
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